ESR1 and triple-negative breast carcinoma: Initially, researchers focused their work on descriptive studies providing a transcriptional atlas of the cellular landscape of estrogen receptor (ER)-positive and triple-negative breast cancer (Wu et al. 2021), as well as HER2-positive breast cancer (Andersson et al. 2021).